NRG and Curium have signed a multi-year contract for the production of molybdenum-99, the starting material for technetium-99m (Tc-99m), the most used radioisotope in nuclear medicine for diagnosing life-threatening diseases such as cardiovascular diseases and cancer.
NRG, which operates the high-flux research reactor (HFR) at Petten in the Netherlands on behalf of its owner, the European commission’s Joint Research Centre, said this renewed collaboration means 30,000 patients a day can continue to rely on nuclear medicine manufacturing capabilities at Petten.
Every year, some 49 million treatments are carried out on patients with nuclear medicines and Tc-99m is used in more than 80% of these examinations.
NRG, which operates the high-flux research reactor (HFR) at Petten in the Netherlands on behalf of its owner, the European commission’s Joint Research Centre, said this renewed collaboration means 30,000 patients a day can continue to rely on nuclear medicine manufacturing capabilities at Petten.
Every year, some 49 million treatments are carried out on patients with nuclear medicines and Tc-99m is used in more than 80% of these examinations.
Want to keep reading?
Register free and get full access to NucNet for 14 days. No card required.
- Daily news briefing on the global nuclear industry
- Weekly, monthly and topical newsletters
- 24/7 coverage during nuclear incidents and safety events
- Full searchable archive, 30,000+ articles since 1991
- SMR and AMR project database
- Analysis, Focus pieces and infographics
- NucNet Style Guide for nuclear reporters and communicators
After the trial, keep a free account for a newsletter and a complimentary Plus article every two weeks. Or see our subscription plans for individuals and organisations.
See subscription options
